Chart pattern: Inverse Head and Shoulders (daily)
▲ Broken out
Broke on Nov 03, 2026 · measured target $51.27 (+6%). Details →
Nov 3, 4:16 PM ET
Omega Healthcare Investors reported third quarter 2026 net income of $87 million and adjusted funds from operations of $262 million, or $0.82 per diluted share. The company raised its full-year 2026 Adjusted FFO guidance range to $3.28 to $3.30 per diluted share and declared a quarterly cash dividend of $0.68 per share.
- Net income for the third quarter of 2026 was $87 million, or $0.27 per diluted share.
- Adjusted Funds From Operations reached $262 million, or $0.82 per diluted share, compared to $243 million, or $0.79 per diluted share, in Q3 2025.
- The company completed $1.5 billion in total new investments year-to-date, including $946 million since quarter-end.
- Full-year 2026 Adjusted FFO guidance was raised to a range of $3.28 to $3.30 per diluted share.
Read the filing on SEC.gov ↗
Oct 1, 8:20 AM ET
Omega Healthcare Investors appointed Matthew P. Gourmand, its President, as President and Chief Executive Officer effective October 1, 2026, succeeding C. Taylor Pickett, who is retiring. Gourmand was also appointed to the Board to fill the seat vacated by Pickett's retirement, with the term expiring in 2027. The filing says Pickett's retirement involved no disagreement with the company on its operations, policies or practices.
- Matthew P. Gourmand, age 51, becomes CEO and director effective October 1, 2026
- He succeeds C. Taylor Pickett, who retires as CEO and from the Board
- Gourmand has served as President since January 1, 2025 and previously led corporate strategy and investor relations
- Board size remains at eight; the Board does not expect to name Gourmand to any committees
Read the filing on SEC.gov ↗
Jul 29, 4:17 PM ET
Omega Healthcare Investors reported second quarter 2026 results on July 29, 2026, with net income of $380 million, or $1.19 per diluted share, up from $140 million, or $0.46 per diluted share, a year earlier. The company also raised its full-year 2026 Adjusted FFO guidance and increased its quarterly dividend by $0.01 to $0.68 per share. For shareholders, the higher earnings, guidance and dividend point to improved results, though net income includes a $246.5 million gain on the sale of 26 facilities.
- Q2 2026 net income was $380 million, or $1.19 per diluted share, versus $140 million, or $0.46, in Q2 2025; results include a $246.5 million gain on asset sales.
- Q2 2026 Adjusted FFO was $261 million, or $0.83 per diluted share, versus $232 million, or $0.77, a year earlier.
- 2026 Adjusted FFO guidance was raised to $3.22 to $3.26 per diluted share from $3.19 to $3.25.
- Quarterly common dividend increased to $0.68 per share, payable August 14, 2026, to holders of record as of August 3, 2026.
Read the filing on SEC.gov ↗
May 21, 4:16 PM ET
Omega Healthcare Investors said its board approved planned leadership changes. President Matthew Gourmand will succeed C. Taylor Pickett as chief executive on October 1, 2026, and Chief Accounting Officer Neal Ballew will succeed Robert Stephenson as chief financial officer on August 1, 2026. The filing cites retirement plans and long-term succession planning, and it reports no financial results.
- Matthew Gourmand, President since January 1, 2025, becomes CEO effective October 1, 2026, and is to join the board; Pickett leaves the board on that date.
- Neal Ballew, Chief Accounting Officer since August 2020, becomes CFO effective August 1, 2026; Lucas Golem becomes Chief Accounting Officer.
- Pickett will receive a consulting fee of $20,000 per month through October 1, 2027; Stephenson will receive $12,000 per month through August 1, 2027.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.